Tango Therapeutics Slides as Investors Appear to Pause Ahead of Next Clinical Catalysts
Tango Therapeutics (TNGX) stock slid 4.9% today, likely due to investor caution ahead of upcoming clinical data. With no recent company press releases, the decline is attributed to profit-taking and a maintained "Hold" rating with a $24 target, as investors await significant late-October clinical updates on vopimetostat combination data and other programs. Insider selling and institutional trading activity also reflect mixed sentiment.
Tango Therapeutics principal accounting officer sells $198k in stock
Jessica Newcomb, Principal Accounting Officer at Tango Therapeutics (NASDAQ:TNGX), sold 8,200 shares of the company's common stock for a total of $198,612 on September 22, 2026. This sale was conducted under a Rule 10b5-1 trading plan, following a significant 178% surge in TNGX shares year-to-date. Despite the stock's performance, InvestingPro analysis indicates it may be overvalued, while recent analyst reports from firms like H.C. Wainwright, Guggenheim, Mizuho, Stifel, and JPMorgan show raised price targets and positive ratings for Tango Therapeutics based on ongoing clinical developments and leadership appointments.
Form 4 Tango Therapeutics Inc For: 24 September By Investing.com
Investing.com reports on a Form 4 filing for Tango Therapeutics Inc (TNGX) related to transactions on September 24th. The article provides the title of the filing, the company's stock symbol and a slight price change, and links to view all comments.
Form 4 Tango Therapeutics Inc For: 24 September By Investing.com
This article from Investing.com reports on the filing of Form 4 for Tango Therapeutics Inc. The brief notice indicates a regulatory filing related to the company for September 24th, without providing further details on the content of the form. The filing is associated with the stock symbol TNGX, which showed a minor increase of 1.18% at the time of publication.
Under a trading plan, Tango Therapeutics (TNGX) officer Jessica Newcomb sold 8,200 shares in three transactions.
Jessica Newcomb, the Principal Accounting Officer of Tango Therapeutics (TNGX), sold a total of 8,200 shares of common stock on September 22, 2026, across three separate transactions. These sales were conducted under a Rule 10b5-1 trading plan established on June 23, 2026, with shares sold at weighted-average prices ranging from $22.8029 to $25.1718. Following these transactions, Newcomb's reported holdings include 59,121 common shares directly owned, which accounts for 43,666 unvested restricted stock units.
Officer at Tango Therapeutics (NASDAQ: TNGX) to sell 15K shares
An officer at Tango Therapeutics (NASDAQ: TNGX), Jessica Newcomb, has filed a Rule 144 notice to sell up to 15,231 shares of the company's common stock, valued at approximately $340,108.23 as of September 22, 2026. The shares were acquired through equity compensation, specifically Employee Stock Purchase Plan vesting and restricted stock unit vesting. The sale will be conducted through Morgan Stanley Smith Barney LLC and represents a small portion of the 168,610,367 shares of common stock outstanding.
Tango Therapeutics (TNGX) Short Interest & Short Float | Updated Sep 2026
This article provides an updated analysis of Tango Therapeutics (TNGX) short interest as of August 31, 2026. It details a 1.29% decrease in short interest since the prior report, with 42.63 million shares sold short, representing 27.04% of the public float. The short interest ratio stands at 19.7 days to cover, indicating a strong pessimistic sentiment among some investors.
Tango Therapeutics at cantor global healthcare: vopimetostat nears approval path
Tango Therapeutics presented at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, highlighting its transition from drug discovery to approval and pre-commercial planning for its lead drug, vopimetostat. The company reported strong early data for vopimetostat, a PRMT5 inhibitor, showing a 92% overall response rate in MTAP-deleted pancreatic cancer when combined with Revolution Medicines’ daraxonrasib. Tango Therapeutics is focusing on securing approval in frontline pancreatic cancer and has over $1 billion in cash to fund the program through Phase III and commercial build-out, while also exploring opportunities in lung cancer and glioblastoma.
Tango Therapeutics' R&D President Adam Crystal Executes Option Exercise and Sells 27,000 Shares Under Rule 10b5-1 Plan
Adam Crystal, President of R&D at Tango Therapeutics (NASDAQ: TNGX), exercised stock options for 27,000 shares at $5.20 per share and subsequently sold all those shares at a weighted average price of $22.367 per share on September 1, 2026. These transactions were executed under a pre-established Rule 10b5-1 trading plan adopted in October 2025. Following these transactions, Crystal directly holds 115,743 shares and retains 260,040 stock options.
Insider at Tango Therapeutics (TNGX) sells 27,000 shares in preset plan
Crystal Adam, President, R&D at Tango Therapeutics (TNGX), exercised stock options and sold 27,000 shares of common stock on September 1, 2026. These transactions, conducted under a Rule 10b5-1 trading plan adopted in October 2025, involved exercising options at $5.20 per share and selling shares at a weighted average price of $22.367. Following these trades, Adam directly held 260,040 stock options and 115,743 shares of common stock.
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
Tango Therapeutics, Inc. announced that its management team will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on September 9, 2026. A live webcast of the event will be available on the company's website, with a replay archived for 90 days. Tango Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for cancer treatment.
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
Tango Therapeutics, Inc. announced its participation in the 2026 Cantor Global Healthcare Conference. Members of the management team are scheduled to present in a fireside chat on Wednesday, September 9, 2026, at 8:35 AM EDT. A live webcast and replay will be available on the company's website.
The Bull Case For Tango Therapeutics (TNGX) Could Change Following $400M ATM Offering And Leadership Shift
Tango Therapeutics (TNGX) recently reported a wider net loss, launched a $400 million at-the-market equity offering, and made key leadership changes focused on commercialization. These moves indicate the company is preparing for later-stage development of vopimetostat, but also highlight potential shareholder dilution. Investors must weigh the potential of vopimetostat against funding risks and the stock's current high expectations.
Trv Gp Iv LLC Makes New Investment in Tango Therapeutics, Inc. $TNGX
Trv Gp Iv LLC has significantly invested in Tango Therapeutics, Inc. (NASDAQ:TNGX) by acquiring over 6.37 million shares, making it their second-largest holding. This investment, valued at approximately $120 billion, represents about 4.41% of Tango Therapeutics. Despite the company missing its recent quarterly EPS estimates, analyst sentiment remains largely positive, with a "Moderate Buy" consensus rating and an average price target of $43.46.
Trv Gp Vi LLC Takes Position in Tango Therapeutics, Inc. $TNGX
Trv Gp Vi LLC has acquired a new stake in Tango Therapeutics, Inc. (NASDAQ:TNGX), purchasing 194,174 shares valued at approximately $6.07 billion, making it their 4th largest position. The article highlights other institutional investments, insider selling, and current analyst ratings, which show a consensus "Moderate Buy" with an average price target of $43.46 despite a recent earnings miss. Tango Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for cancer.
TANGO THERAPEUTICS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $68 FROM $66
H.C. Wainwright has increased its target price for Tango Therapeutics, Inc. (TNGX.O) from $66 to $68. This update reflects a positive adjustment in the firm's outlook for the biotechnology company. The news was reported by Reuters.
The Bull Case For Tango Therapeutics (TNGX) Could Change Following $400M ATM Offering And Leadership Shift
Tango Therapeutics recently announced a wider net loss, a $400 million at-the-market equity offering, and leadership changes aimed at bolstering its commercialization efforts. These strategic moves suggest the company is preparing vopimetostat for late-stage development and commercial launch, though they also highlight potential shareholder dilution. The stock's current valuation already reflects high expectations despite the company's distant profitability.
H.C. Wainwright raises Tango Therapeutics price target to $68
H.C. Wainwright raised its price target for Tango Therapeutics (NASDAQ: TNGX) to $68 from $66, maintaining a Buy rating despite the stock's 250% surge over the past year. The adjustment followed the company's Q2 2026 results, which showed a larger net loss than estimated, but a strong cash position of approximately $1 billion. This update aligns with other recent positive analyst coverage and strategic developments for Tango Therapeutics.
Tango Therapeutics (NASDAQ:TNGX) Given New $68.00 Price Target at HC Wainwright
HC Wainwright has increased its price target for Tango Therapeutics (NASDAQ:TNGX) to $68.00 from $66.00, maintaining a "buy" rating and suggesting a significant upside. This comes despite the company reporting a quarterly loss of $0.37 per share, missing the consensus estimate. Tango Therapeutics currently holds a "Moderate Buy" consensus rating from analysts, with an average price target of $43.46.
H.C. Wainwright raises Tango Therapeutics price target to $68 By Investing.com
H.C. Wainwright has increased its price target for Tango Therapeutics Inc. (NASDAQ:TNGX) shares to $68 from $66, maintaining a Buy rating. This adjustment follows the company's Q2 2026 results, which showed a higher net loss than previously estimated, but also revealed a strong cash position of approximately $1 billion. The firm believes this cash reserve could provide an operational runway potentially into profitability, and the new target aligns with a strong Buy consensus despite a significant stock surge over the past year.
H.C. Wainwright raises Tango Therapeutics price target to $68
H.C. Wainwright increased its price target for Tango Therapeutics (NASDAQ: TNGX) to $68 from $66, while maintaining a Buy rating, following the company's Q2 2026 results. Despite Tango reporting a larger net loss than anticipated, the firm highlighted the company's strong cash position of approximately $1 billion, which could provide an operational runway into profitability. This positive outlook is echoed by other analysts, with recent upgrades and target increases from Jefferies, JPMorgan, Mizuho, and Guggenheim, reflecting ongoing advancements in their clinical trials and strategic appointments.
Stifel reiterates Tango Therapeutics stock rating with $40 target
Stifel has reaffirmed its Buy rating for Tango Therapeutics Inc. (NASDAQ:TNGX) with a price target of $40.00, despite the stock appearing overvalued relative to its Fair Value estimate. The firm anticipates positive longer follow-up data from an upcoming ESMO 2026 presentation regarding the company's vopimetostat plus RAS(ON) inhibitor combination, particularly in pancreatic ductal adenocarcinoma, which could maintain the high objective response rate. This comes amid significant clinical progress and analyst upgrades from Guggenheim, Mizuho, JPMorgan, and Jefferies, reflecting growing optimism in Tango Therapeutics' cancer treatments.
Tango Therapeutics (TNGX) investors report 0% beneficial ownership in latest 13G/A
An amended Schedule 13G filing for Tango Therapeutics (TNGX) reveals that Nextech Crossover I SCSp, Nextech Crossover I GP S.a r.l., and individuals Ian Charoub, Costas Constantinides, and Rocco Sgobbo now report 0 beneficial shares, equating to 0.0% ownership as of June 30, 2026. These reporting persons indicate they hold 5 percent or less of Tango Therapeutics' common stock and possess no sole or shared voting or dispositive power. The filing confirms their status below the 5% Schedule 13G reporting threshold.
Goldman Sachs Group (TNGX) discloses 6.0% beneficial stake in Tango Therapeutics
The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have disclosed a 6.0% beneficial ownership stake in Tango Therapeutics, Inc. (TNGX) through a Schedule 13G filing. This holding amounts to 9,742,402.80 shares and signifies shared voting and dispositive power over a significant portion of Tango's common stock. The filing identifies Goldman Sachs & Co. LLC as a broker-dealer and investment adviser, with The Goldman Sachs Group, Inc. acting as a parent holding company.
Farallon group discloses 16.27M Tango Therapeutics (TNGX) shares and warrants
Farallon Capital Management, L.L.C. and its affiliated funds have disclosed a beneficial ownership of 16,270,187 shares of Tango Therapeutics (TNGX), representing 9.8% of the company's outstanding common stock. This includes 12,277,000 directly held shares and 3,993,187 pre-funded common stock purchase warrants, which are exercisable within 60 days, subject to a 9.99% beneficial ownership limitation. The disclosure was made in an amended Schedule 13G/A SEC filing.
Handelsbanken Fonder AB Acquires Shares of 287,900 Tango Therapeutics, Inc. $TNGX
Handelsbanken Fonder AB has acquired 287,900 shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) for approximately $9 million, establishing a 0.20% stake in the company. Institutional investors now collectively own nearly 79% of Tango Therapeutics, a clinical-stage biotechnology company focused on precision cancer medicines. The company currently holds a "Moderate Buy" consensus rating from analysts, with an average price target of $43.31, despite reporting a wider-than-expected quarterly loss.
Tango Therapeutics (TNGX) Is Getting Fresh Attention, What Are Investors Looking At?
Tango Therapeutics (TNGX) recently saw investor attention due to a wider Q2 net loss, the cessation of collaboration revenue, and a new US$400 million at-the-market equity offering which could dilute shareholders. Despite short-term share price drops, the stock shows strong momentum over longer periods, with significant year-to-date and one-year returns, indicating shifting expectations for its pipeline. The company trades below analyst targets and intrinsic value, presenting a potential opportunity, though it faces risks like ongoing losses and reliance on its oncology pipeline.
Tema ETFs LLC Buys New Holdings in Tango Therapeutics, Inc. $TNGX
Tema ETFs LLC has acquired a new stake of 55,384 shares in Tango Therapeutics, Inc. (NASDAQ:TNGX), valued at approximately $1.73 million. Other institutional investors have also adjusted their holdings, and company insider Adam Crystal sold 27,000 shares. Despite missing EPS estimates, analysts maintain a "Moderate Buy" rating with an average price target of $43.31, significantly above its current trading price of $25.58.
Adage Capital discloses 3.44% Tango Therapeutics (TNGX) stake in 13G/A filing
Adage Capital Management, L.P. and associated parties have disclosed a 3.44% beneficial ownership stake in Tango Therapeutics, Inc. (TNGX) through a Schedule 13G/A filing. This ownership amounts to 5,600,000 shares, with both shared voting and shared dispositive power. The percentage is calculated based on 162,814,649 outstanding shares of Tango Therapeutics.
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses
Tango Therapeutics (TNGX) reported a wider-than-expected loss of 37 cents per share in Q2 2026, missing the Zacks Consensus Estimate of 31 cents, leading to a 4.8% stock dip. The company recorded no collaboration revenues as its agreement with Gilead concluded, and operating expenses significantly increased due to higher R&D for clinical programs and a near doubling of general and administrative costs. Despite the earnings miss, TNGX highlighted progress in its pipeline, particularly with lead candidate vopimetostat in combination with daraxonrasib for pancreatic cancer.
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses
Tango Therapeutics (TNGX) reported a wider-than-expected loss of 37 cents per share in Q2 2026, missing the Zacks Consensus Estimate of 31 cents, primarily due to higher operating expenses and no collaboration revenues. Despite the earnings miss causing a 4.8% stock dip, TNGX shares have surged 197.3% year-to-date. The company is advancing its lead pipeline candidate, vopimetostat, with promising clinical data in pancreatic cancer and plans for a phase III study.
Guggenheim raises Tango Therapeutics stock price target to $35
Guggenheim raised its price target for Tango Therapeutics Inc. (NASDAQ:TNGX) to $35 from $32, maintaining a Buy rating, following the company's Q2 2026 results and plans for a Phase 3 trial. Despite the stock's significant increase over the past year, InvestingPro suggests it is currently overvalued. The company anticipates several key updates and trial initiations in the second half of 2026.
Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
Tango Therapeutics announced its second quarter 2026 financial results, highlighting significant progress in its clinical pipeline, particularly with vopimetostat for pancreatic cancer, which showed a 92% objective response rate in Phase 1/2 trials. The company is preparing for late-stage clinical advancement and potential commercialization, supported by a strong cash position of $1.0 billion. Key leadership appointments have also been made to bolster these efforts.
Tango Therapeutics (TNGX) Stock Faces Cash Burn Pressure After Revenue Vanishes
Tango Therapeutics (TNGX) reported a net loss of US$100.9m and zero revenue for H1 2026, widening its loss from the previous year, although its balance sheet has improved due to a large equity raise earlier in 2026. The company, an early-stage oncology player, is facing scrutiny over its cash burn and reliance on its pipeline for future success, as its stock dropped about 5% today and 15% over the past 30 days. Despite recent leadership hires focused on commercialization, the absence of product revenue and increased losses highlight the significant financial pressures and the importance of successful development for the biotech firm.
Tango Therapeutics (TNGX) Stock Faces Cash Burn Pressure After Revenue Vanishes
Tango Therapeutics (TNGX) saw its stock drop by about 5% after reporting a widened net loss of US$100.9m and zero revenue for the first half of 2026, compared to US$8.6m in the prior year. Despite a significant equity raise earlier in the year, the company, an early-stage oncology developer, faces pressure from its cash burn and the absence of product revenue, highlighting its reliance on future funding and successful pipeline development. The balance sheet, however, is better positioned to sustain current spending, while new leadership hires suggest a focus on commercialization.
Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $44.58, Implies 61% Upside
Analysts have increased the average 12-month price target for Tango Therapeutics, Inc. (TNGX) stock from $44.33 to $44.58, with a range of $24 to $69 per share. This updated target suggests a 61% potential upside based on the Aug. 10 closing price. The consensus rating from 13 analysts remains a "Buy," with 12 Buy ratings and 1 Hold.
Why is Tango Therapeutics stock sliding today?
Tango Therapeutics (TNGX) stock fell nearly 4.0% after the company reported Q2 2026 financial results that missed Wall Street expectations, with a wider net loss per share and zero revenue. Operating costs, particularly general and administrative expenses, nearly doubled year-over-year. Despite progress in clinical trials, investors focused on the financial shortfall and a mildly risk-off broader market contributed to the stock's decline.
Tango Therapeutics faces earnings test as PRMT5 data fuels rally
Tango Therapeutics (NASDAQ: TNGX) is set to report its second-quarter earnings, with investors keenly anticipating updates on its PRMT5 inhibitor programs, particularly the progress toward a Phase 3 pancreatic cancer trial. The clinical-stage biotech has seen its stock rally due to promising combination data, and analysts are bullish with a mean price target implying significant upside. Key areas of focus for investors include regulatory feedback, enrollment strategies for trials, cash burn, and data readouts for lung cancer and glioblastoma programs, especially given increasing competition in the MTAP-deleted cancer space.
Tango Therapeutics faces earnings test as PRMT5 data fuels rally
Tango Therapeutics (TNGX) is set to report its second-quarter results, with investors closely watching for updates on its PRMT5 inhibitor programs and its path to a pivotal pancreatic cancer trial. The company's stock has rallied significantly due to promising combination data, and analysts are largely bullish, expecting clarity on regulatory feedback, enrollment strategies, and cash burn. The focus will be on whether Tango can translate its clinical success into a clear regulatory and commercial pathway amidst intensifying competitive dynamics.
Tango Therapeutics, Inc. Q2 2026: Revenue $0 Net loss $55.34M, EPS ($0.37) — 10-Q Summary
Tango Therapeutics, Inc. reported Q2 2026 financial results with $0 revenue, a net loss of $55.34 million, and a diluted EPS loss of $0.37. The company's financial performance worsened year-over-year due to increased spending on its PRMT5 programs and expanded clinical operations. Despite the losses, Tango Therapeutics is advancing Phase 1/2 vopimetostat combination trials and is planning a Phase 3 study for MTAP-deleted PDAC.
Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
Tango Therapeutics announced its second-quarter 2026 financial results, highlighting a pivotal period with positive Phase 1/2 data for vopimetostat plus daraxonrasib in pancreatic cancer, achieving a 92% objective response rate. The company is preparing for late-stage clinical advancement and has strengthened its leadership team with new appointments to support commercialization efforts. Tango reported a cash position of $1.0 billion as of June 30, 2026, which is expected to fund its operating plan through planned development and commercialization preparation.
345,156 Shares in Tango Therapeutics, Inc. $TNGX Acquired by Assenagon Asset Management S.A.
Assenagon Asset Management S.A. recently acquired 345,156 shares of Tango Therapeutics (NASDAQ:TNGX) worth approximately $10.79 million, giving them a 0.24% stake in the company. Other institutional investors also adjusted their positions in Tango Therapeutics, while insider Adam Crystal sold 27,000 shares for about $798,930. The company reported a quarterly EPS in line with analyst expectations and maintains a "Moderate Buy" consensus rating with an average price target of $42.15.
The Manufacturers Life Insurance Company Boosts Holdings in Tango Therapeutics, Inc. $TNGX
The Manufacturers Life Insurance Company significantly increased its stake in Tango Therapeutics, Inc. (NASDAQ:TNGX) by 234.6% in the first quarter, now holding 108,218 shares valued at approximately $2.26 million. Institutional investors collectively own 78.99% of the company, which reported quarterly EPS in line with analyst expectations. Despite a broadly positive analyst sentiment with a consensus price target of $42.15, an insider recently sold 27,000 shares.
Form 8K Tango Therapeutics Inc For: 7 August By Investing.com
This article announces that Tango Therapeutics Inc. filed a Form 8K on August 7th. It is a brief financial news update from Investing.com, highlighting the filing with the Securities and Exchange Commission (SEC). The article also notes a 6.66% decline in Tango Therapeutics' stock symbol TNGX.
Tango Therapeutics Announces Executive Chair Barbara Weber’s Departure
Tango Therapeutics announced that Executive Chair Dr. Barbara Weber's employment ended on August 3, 2026, and she resigned from all positions without disagreement. Her departure aligns with an amended employment agreement, and she will receive a separation package including salary continuation, COBRA reimbursement, and accelerated equity vesting. This transition is presented as an orderly contractual change, aiming to assure investors of governance stability amidst her departure.
Tango Therapeutics (NASDAQ:TNGX) Trading Down 6.1% - What's Next?
Tango Therapeutics (NASDAQ:TNGX) experienced a 6.1% decline in its share price during midday trading, closing at $27.24 with a significant 86% decrease in trading volume compared to its average. Despite the drop, analyst sentiment remains largely positive with a "Moderate Buy" consensus and an average price target of $42.15. The company recently met earnings per share expectations, and institutional investors hold a substantial portion of its shares, although an insider recently sold a considerable block of stock.
Tango Therapeutics (NASDAQ: TNGX) outlines Barbara Weber separation package
Tango Therapeutics (NASDAQ: TNGX) has detailed the separation agreement with its former Executive Chair, Dr. Barbara Weber, whose employment and board roles ended on August 3, 2026. The agreement, executed on August 6, 2026, includes base-salary severance and COBRA reimbursement through December 31, 2026, full acceleration of outstanding options and RSUs, and a pro-rata 2026 annual incentive. These benefits are conditional upon her not revoking the agreement.
Tango Therapeutics Announces Executive Chair Transition
Tango Therapeutics, Inc. (NASDAQ: TNGX) announced that Dr. Barbara Weber, Executive Chairman of its Board of Directors, will be stepping down to pursue other interests. The company expressed gratitude for her vision, leadership, and commitment. Tango Therapeutics is a clinical-stage biotechnology company focused on discovering and developing precision cancer medicines using the principle of synthetic lethality.
Form 8K Tango Therapeutics Inc For: 7 August By Investing.com
This article announces that Tango Therapeutics Inc. filed a Form 8K on August 7. The filing is brief, simply stating the company name and the filing date, and does not provide further details within the article content.
Certain Stock Options of Tango Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 8-AUG-2026.
Certain stock options of Tango Therapeutics, Inc. (TNGX) are under a 60-day lock-up agreement, preventing sales or transfers from June 9, 2026, until August 8, 2026. This restriction applies to directors and executive officers and covers common stock and convertible securities. The agreement aims to stabilize the stock price after an offering, with J.P. Morgan Securities LLC and Leerink Partners LLC managing exceptions.
